LGG

Linkage of Cancer and Lupus in Gliomas Patients

Retrieved on: 
Monday, March 25, 2024
CD86, OS, TME, Gene, Transforming growth factor beta, CD68, Survival, LGG, Ligand, TGFB2, CD276, IDH, STAT1, Inflammation, Central nervous system, Patient, RNA, Tumor microenvironment, Cancer, Messenger, Macrophage, SLE, Expression, TAM, Treatment, Neoplasm, IRF5, Therapy, TGF, IRF1, TGFB, OTCQB, Demethylation, Vaccine

Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).
  • Understanding the role of IRF5 in both SLE and cancer opens an avenue for targeting IRF5 or its downstream pathways.
  • LGG patients expressing high levels of TGFB2 and IFNGR2 are over-represented in IDH wild-type tumor samples, suggesting that TGFB2 and IFNGR2 mRNA can be therapeutically targeted in these high-risk patients.
  • Therefore, to improve OS in LGG patients, combination therapies must target TGFB2 and IFN-γ activation (via IRF5 inhibition) or immune therapies targeted against CD276/B7-H3

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System

Retrieved on: 
Thursday, March 7, 2024
SAN, Medical college, Medical College of Wisconsin, Vancouver General Hospital, DSM-IV codes, American College, ACMG, OGM, LGG, Medical genetics, DRS, Research, Cancer, Medical device

Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis

Key Points: 
  • Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis
    A scientific platform presentation will feature Drs.
  • ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research.
  • The ACMG conference will be held March 12-16, 2024, in Toronto, Canada.
  • All scientific posters will be presented in Exhibit Halls DE.

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Fever, Fatigue, ATC, Vincristine, HGG, BRAF, EMA, Xeroderma, Carboplatin, International, Bleeding, Cough, Headache, Nausea, Neutropenia, Language, Neoplasm, Cancer, Mutation, Neutrophil, Radiation, Water, European Medicines Agency, Tablet, MEK, Growth, Select, Patient, Cell, LGG, Safety, Anatomy, Vomiting, IIA, Rash, Medical device

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Fever, Fatigue, ATC, Vincristine, HGG, BRAF, EMA, Xeroderma, Carboplatin, International, Bleeding, Cough, Headache, Nausea, Neutropenia, Language, Neoplasm, Cancer, Mutation, Neutrophil, Radiation, Water, European Medicines Agency, Tablet, MEK, Growth, Select, Patient, Cell, LGG, Safety, Anatomy, Vomiting, IIA, Rash, Medical device

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Fever, Fatigue, ATC, Vincristine, HGG, BRAF, EMA, Xeroderma, Carboplatin, International, Bleeding, Cough, Headache, Nausea, Neutropenia, Language, Neoplasm, Cancer, Mutation, Neutrophil, Radiation, Water, European Medicines Agency, Tablet, MEK, Growth, Select, Patient, Cell, LGG, Safety, Anatomy, Vomiting, IIA, Rash, Medical device

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Retrieved on: 
Monday, December 18, 2023
Carboplatin, Vomiting, Cough, Anatomy, Select, ATC, Safety, Radiation, Neutrophil, European Medicines Agency, Rash, MEK, HGG, International, INN, Headache, Language, Tablet, EMA, Patient, IIA, Marketing, Neoplasm, Medical Subject Headings, Diarrhea, Neutropenia, BRAF, Vincristine, Bleeding, Cancer, Nausea, Water, Growth, Fatigue, Xeroderma, LGG, Fever, Mutation, Cell, Instrumentation, Medical imaging, Pharmaceutical industry, Medicinal plants, Medical device, Vaccine, Mobile phone, Online shopping, Bookkeeping, Glioma, Medicine

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Atlas Air Takes Delivery of Second of Four New Boeing 777-200 Freighters

Retrieved on: 
Thursday, July 20, 2023
Insurance, LGG, Maintenance, Partnership, Atlas Air, NLU, Senior, Boeing, Air cargo, Airport, XMN, MSC, Boeing 777, Atmosphere of Earth, ICN, ACMI, Aircraft, Airline, IND

This is the second of four Boeing 777-200 Freighters that Atlas Air will operate for MSC, which will complement the existing weekly service for the world’s largest shipping company.

Key Points: 
  • This is the second of four Boeing 777-200 Freighters that Atlas Air will operate for MSC, which will complement the existing weekly service for the world’s largest shipping company.
  • “Building on the successful launch of MSC’s Air Cargo Solution, we are very pleased to welcome this second 777 delivery as part of our long-term strategic partnership.
  • We expect our remaining two 777 aircraft to be delivered in the fourth quarter,” said Michael Steen, Chief Executive Officer, Atlas Air Worldwide.
  • In partnership with Atlas Air, we have built a solid foundation on which to expand our air cargo solution,” said Jannie Davel, Senior Vice President Air Cargo at MSC.

Vinamilk forms strategic partnerships with top global companies and receives Purity Award for children's milk powder

Retrieved on: 
Friday, June 16, 2023
LGG, CHR, DSM, Partnership, Nucleotide, Nutrient, Research, USD, Trust, AAK, Probiotic, Breast milk, Drug, Pharmaceutical industry, Vinamilk, GNOSIS

The collaboration reinforces Vinamilk's international reputation and its strong commitment to providing high-quality baby milk powder of international standards.

Key Points: 
  • The collaboration reinforces Vinamilk's international reputation and its strong commitment to providing high-quality baby milk powder of international standards.
  • Six leading global nutrition and bioscience companies have partnered with Vinamilk in Vietnam including DSM (Switzerland), CHR HANSEN (Denmark), BENEO (Germany), GNOSIS (Italy), AAK (Sweden), and KANEMATSU (Japan).
  • Through these strategic collaborations, Vinamilk is committed to delivering international-quality nutritional solutions, featuring superior formulations to the young generation of Vietnam.
  • Hence, I believe that with this stronger strategic partnership, Vinamilk will soon conquer the highest global standards in the dairy industry."

Vinamilk forms strategic partnerships with top global companies and receives Purity Award for children's milk powder

Retrieved on: 
Friday, June 16, 2023
LGG, CHR, DSM, Partnership, Nucleotide, Nutrient, Research, USD, Trust, AAK, Probiotic, Breast milk, Drug, Pharmaceutical industry, Vinamilk, GNOSIS

The collaboration reinforces Vinamilk's international reputation and its strong commitment to providing high-quality baby milk powder of international standards.

Key Points: 
  • The collaboration reinforces Vinamilk's international reputation and its strong commitment to providing high-quality baby milk powder of international standards.
  • Six leading global nutrition and bioscience companies have partnered with Vinamilk in Vietnam including DSM (Switzerland), CHR HANSEN (Denmark), BENEO (Germany), GNOSIS (Italy), AAK (Sweden), and KANEMATSU (Japan).
  • Through these strategic collaborations, Vinamilk is committed to delivering international-quality nutritional solutions, featuring superior formulations to the young generation of Vietnam.
  • Hence, I believe that with this stronger strategic partnership, Vinamilk will soon conquer the highest global standards in the dairy industry."

Ligand Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 4, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, Telephone, Fulvestrant, GAAP, Congress, Investment, Focal segmental glomerulosclerosis, Patient, NYSE, PROTECT, Novartis, LGG, NASH, Mutation, Element, Forecasting, EMA, Proteinuria, Molluscum contagiosum, PDUFA, Growth, SB206, FDA, Lancet, THC, Total, Safety, Pelican, CDK, Microcystic lymphatic malformation, COVID-19, FSGS, BRAF, Immunoglobulin A, Research, Therapy, NVS, ESR1, NDA, Income tax, Woman, Sale, Trial of the century, Nephrology, Physician, EPS, Breast cancer, Cryptocurrency, Pharmaceutical industry, Travers Smith, Ligand, IgA nephropathy

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates.
  • Core Captisol sales were $10.6 million for the first quarter of 2023, compared with $6.2 million for the same period in 2022.
  • Contract revenue was $16.2 million for the first quarter of 2023, compared with $11.0 million for the same period in 2022.
  • Ligand is increasing 2023 revenue and EPS guidance provided on its fourth quarter earnings call held on February 22, 2023.